Payers vs. industry - the conundrum of gene therapy pricing and reimbursement in Germany

Fri, 2019 / 01 / 25

About the author

Ihr Ansprechpartner Prof. Matthias P. Schönermark, M.D., Ph.D.

Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director

Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

E-Mail More Contact Info

The topic “The conundrum of gene therapy pricing and reimbursement in Germany- how to align the interests of payers and industry” had thoroughly been investigated at SKC consulting within the last months. Johannes Wolff, student for Drug Discovery and Pharma Management at the University College London (School of Pharmacy), examined this conundrum and possible solutions in his master thesis as a working student of SKC. Hereby, Johannes Wolff graduates very successful with grade “distinction” (top of his class).

SKC congratulates him and wishes success for his promotion at the Institute of Manufacturing, University of Cambridge. The PhD thesis should compare criteria and hurdles for research and development alliance formations across industry borders of pharma and tech-partnering for emerging digital health technologies.

SKC consulting has broad expertise for the market access of gene therapies. Please read our corresponding white paper “Successful market access for gene therapies – Strategic solutions and best practice”, as well.

BY Prof. Matthias P. Schönermark, M.D., Ph.D., managing director and Karolin Priese, Dipl-Kauffrau